Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 07/30/15 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 07/20/15 | 8-K | Current report filing |
|
4 | |
| 07/06/15 | 8-K | Current report filing |
|
7 | |
| 06/23/15 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
32 | |
| 06/23/15 | 8-K | Current report filing |
|
69 | |
| 06/09/15 | EFFECT | Notice of Effectiveness |
|
1 | |
| 06/05/15 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 06/04/15 | 8-K | Current report filing |
|
4 | |
| 06/03/15 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
3 | |
| 06/03/15 | S-3/A | Registration statement for specified transactions by certain issuers |
|
41 |
